EICHORCondition: Endometrial Cancer · Sponsor: MiMARK Diagnostics, S.L.
CYTOMARK, a non-invasive in vitro diagnostic (IVD) test measuring a defined panel of protein biomarkers in cervical fluid, can accurately detect endometrial cancer in both symptomatic and asymptomatic women at high risk for the disease. The aim of the study consists in validating CYTOMARK's ELISA test, creating and freezing an algorithm detect EC in post-menopausal women with abnormal uterine bleeding (AUB).
This description comes directly from the study's public registry record.
Antonio Gil-Moreno, MD, PhD · 934893066 · antonio.gil@vallhebron.cat
Eva Colás, PhD · 934893066 · eva.colas@mimark.es
Always discuss trial participation with your own doctor first.
| Hospital Universitari de Bellvitge | L'Hospitalet de Llobregat, Barcelona, Spain | Recruiting |
| Hospital Universitari Campus Vall d'Hebron | Barcelona, Spain | Recruiting |
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07148154